{"filing":{"accession_number":"0001720580-26-000054","cik":"0001720580","ticker":"ACET","company_name":"Adicet Bio, Inc.","form":"8-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"acet-20260901.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1720580/000172058026000054/acet-20260901.htm"},"events":[{"id":30769,"run_id":28207,"accession_number":"0001720580-26-000054","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces completion of the last patient visit for a Phase 1 clinical trial of prula-cel in SLE patients, with topline results expected in September 2026, along with updates on FDA clearance of an IND for ADI-212 and advancement of an in vivo CAR-T platform. These are material clinical and regulatory milestones for a clinical-stage biotech company, but do not fit neatly into earnings, M\u0026A, impairment, or other specific event categories. The event is clearly operational/strategic in nature—clinical trial progress and pipeline advancement—making operational_other the most appropriate classification.","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-09-01","form":"8-K","submitted_at":null,"items":[{"id":33475,"accession_number":"0001720580-26-000054","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of the last patient visit for a Phase 1 clinical trial of prula-cel in SLE patients, with topline results expected in September 2026, along with updates on FDA clearance of an IND for ADI-212 and advancement of an in vivo CAR-T platform. These are material clinical and regulatory milestones for a clinical-stage biotech company, but do not fit neatly into earnings, M\u0026A, impairment, or other specific event categories. The event is clearly operational/strategic in nature—clinical trial progress and pipeline advancement—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:03:43.579037+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33475,"accession_number":"0001720580-26-000054","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of the last patient visit for a Phase 1 clinical trial of prula-cel in SLE patients, with topline results expected in September 2026, along with updates on FDA clearance of an IND for ADI-212 and advancement of an in vivo CAR-T platform. These are material clinical and regulatory milestones for a clinical-stage biotech company, but do not fit neatly into earnings, M\u0026A, impairment, or other specific event categories. The event is clearly operational/strategic in nature—clinical trial progress and pipeline advancement—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-01T11:03:43.579037+00:00","company_name":"Adicet Bio, Inc.","ticker":"ACET","filing_date":"2026-09-01"}]}